Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Drug Eluting Balloon for Prevention of Constrictive Remodeling

This study has been terminated.
(recruitment was not sufficient.)
Information provided by (Responsible Party):
Prof. Dr. med. Christoph Hehrlein, Herz-Zentrums Bad Krozingen Identifier:
First received: September 19, 2012
Last updated: April 27, 2017
Last verified: April 2017
Earlier studies indicated that Percutaneous coronary intervention (PCI) may be problematic in diffuse small vessel disease especially of diabetic patients. High restenosis rates after balloon only procedures in small vessels occur due to negative constrictive vessel remodeling if DES (drug eluting stents) are not used and prolonged anti-platelet therapy is not indicated. The main hypothesis of the trial is that in analogy to DCB success in peripheral arterial disease (PAD), cellular toxicity of the drug paclitaxel eluting from a IN.PACT FalconTM DCB will prevent constrictive remodelling of small coronary vessel segments after dilatation. The IN.PACT FalconTM DCB is compared with plain old balloon angioplasty (POBA) using a Sprinter LegendTM balloon in small vessel coronary artery disease. A constrictive remodelling process will be measured by optical coherence tomography (OCT) at 9 months median F/U. This pilot trial is planned to be randomized 1:1 for DCB against POBA therapy.

Condition Intervention
Coronary Disease
Diabetes Mellitus
Device: Paclitaxel coated balloon catheter
Device: uncoated balloon catheter "sprinter legend"

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Drug Coated Balloon (DCB) for the Prevention of Constrictive Remodeling and Restenosis in Small Vessel Coronary Disease

Resource links provided by NLM:

Further study details as provided by Prof. Dr. med. Christoph Hehrlein, Herz-Zentrums Bad Krozingen:

Primary Outcome Measures:
  • MACE-rate [ Time Frame: 12 months after initial treatment ]
    combined end-point: death, myocardial infarction and revascularisation of the target lesion

Secondary Outcome Measures:
  • OCT-measurement [ Time Frame: during follow-up, after 9 months ]
    each symptomatic patient will be examined using optical coherence tomography to detect, if the symptoms are caused by a narrowing at the target lesion

Enrollment: 14
Study Start Date: October 2012
Study Completion Date: April 2017
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Paclitaxel coated balloon catheter
Paclitaxel coated balloon catheter "IN.PACT Falcon"
Device: Paclitaxel coated balloon catheter
Dilatation of the target lesion
Other Name: IN.PACT Falcon
Active Comparator: uncoated balloon catheter
uncoated balloon catheter "sprinter legend"
Device: uncoated balloon catheter "sprinter legend"
Dilatation of the target lesion
Other Name: sprinter legend


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • at least one target lesion with a stenosis severity ≥ 50% in one coronary segment with a diameter ≤ 2.5 mm
  • age > 18 years
  • weight > 45 kg
  • patient suitable for balloon dilatation and not suitable for elective implantation of a drug eluting stent
  • insulin-dependent or non-insulin-dependent diabetes mellitus
  • length of lesion ≥ 15 mm

Exclusion Criteria:

  • Life expectancy < 12 months
  • In-Stent restenosis
  • planned coronary bypass or heart valve OP
  • ST elevation myocardial infarction within the last 72 hours
  • cardiogenic shock
  • renal impairment or liver dysfunction (creatinine > 2.0 mg/dl, AST/ALT > 3x of normal value
  • incompliance
  • pregnant or breastfeeding women or women who like to be pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01690572

Department of Cardiology and Angiology I, Heart Center,
Freiburg, Baden-Württemberg, Germany, 79106
Sponsors and Collaborators
Prof. Dr. med. Christoph Hehrlein
Principal Investigator: Christoph Hehrlein, Prof. Dr. Department of Cardiology and Angiology I, Heart Center, Freiburg University
  More Information

Responsible Party: Prof. Dr. med. Christoph Hehrlein, Professor Dr. med., Herz-Zentrums Bad Krozingen Identifier: NCT01690572     History of Changes
Other Study ID Numbers: DEBT
Study First Received: September 19, 2012
Last Updated: April 27, 2017

Keywords provided by Prof. Dr. med. Christoph Hehrlein, Herz-Zentrums Bad Krozingen:
drug eluting balloon
constrictive remodeling

Additional relevant MeSH terms:
Diabetes Mellitus
Coronary Disease
Coronary Artery Disease
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Albumin-Bound Paclitaxel
Hyaluronic Acid
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents processed this record on May 25, 2017